Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Csorna – page 15

186 clinical trials in Csorna, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Csorna at a glance
186
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

186 trials in Csorna

Open in trial search

Study on the Effectiveness and Safety of CAM2029 Compared to Octreotide and Lanreotide in Patients with Gastroenteropancreatic Neuroendocrine Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Camurus AB

Colitis ulcerative

Not recruiting

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study to Test Pembrolizumab, MK-4830, and MK-0482 in Patients with Advanced Non-Small Cell Lung Cancer Who Have Not Received Prior Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:MK-0482
  • Sponsor:Merck Sharp & Dohme LLC

Study of Boserolimab, MK-0482, and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-(L)1 Therapy

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Enzalutamide
  • Sponsor:Merck Sharp & Dohme LLC

Study on the Safety and Effectiveness of Stereotactic Body Radiotherapy with or without Pembrolizumab for Patients with Unresected Stage I or II Non-Small Cell Lung Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Vericiguat for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Breast cancer

Not recruiting

Study Comparing ARV-471 and Fulvestrant for Patients with Advanced Estrogen Receptor-Positive, HER2-Negative Breast Cancer After Endocrine Treatment

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Pfizer Inc.

Bladder cancer

Not recruiting

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Pembrolizumab and Lenvatinib with Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Previous Treatments

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Lenvatinib
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Csorna

What the registry says about research in the country

01 Respiratory Conditions

Innovative research focusing on Chronic Obstructive Pulmonary Disease (COPD) treatment optimization through add-on therapies to standard triple medication regimens. Clinical trials aim to reduce the frequency and severity of exacerbations in COPD patients.

  • COPD Management
  • Exacerbation Prevention
  • Triple Therapy Enhancement

Studies evaluating new therapeutic approaches over 52-week periods to ensure long-term effectiveness and safety.

02 Chronic Cough Research

Groundbreaking studies targeting Refractory Chronic Cough and unexplained chronic cough conditions. Research focuses on evaluating novel therapeutic compounds to reduce cough frequency in adult patients.

  • Cough Frequency Assessment
  • Treatment Safety Evaluation
  • Long-term Effectiveness

Comprehensive 52-week trials combining efficacy assessment with safety monitoring for chronic cough management.

03 Chronic Bronchitis Studies

Advanced research examining the intersection of COPD and Chronic Bronchitis, focusing on innovative therapeutic approaches. Trials evaluate medication efficacy for patients with complex respiratory conditions.

  • Combined Treatment Approaches
  • Disease Management
  • Patient Response Monitoring

Investigation of dual-dose treatments to enhance standard respiratory care protocols.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.